Dear ,
In the current issue of the OncoWuXi Newsletter, we would like to share with you our updates on genetically engineered Ba/F3 cell lines and corresponding
in vivo/in vitro
validation data. Other interesting topics covered in this issue include our
in vivo
efficacy platform for bispecific antibodies,
and CLDN18.2 targeted
in vivo
models.
OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi AppTec Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.